Proteases play a regulatory role in a variety of pathologies including cancer, pancreatitis, thromboembolic disorders, viral infections and many others. One of the possible strategies how to combat with these pathologies seems to be the use of low molecular inhibitors. Natural products were evaluated in the in vitro antiprotease assay on serine proteases (trypsin, thrombin and urokinase) and on the cysteine protease cathepsin B. We found interesting results for -ursolic acid isolated from Salvia officinalis, which significantly inhibited all tested proteases in vitro in the micromolar range. -Ursolic acid showed the strongest inhibition activity to urokinase (IC 50 = 12 μm) and cathepsin B (IC 50 = 10 μm) as proteases included in tumour invasion and metastasis indicated possible anticancer effectivity. Therefore, we tested the ability of -ursolic acid at doses of 50, 75 and 100 mg/kg given i.p. to inhibit lung colonization of B16 mouse melanoma cells in vivo. We found, that -ursolic acid significantly decreased the number of B16 colonies in the lungs of mice at the dose 50 mg/kg (p Ͻ 0.05).
Introduction
Salvia officinalis L. is an old medicinal plant widely used in traditional folk medicine (Lu and Foo, 2002; Slameň ová et al., 2004) . Salvia species (Lamiaceae) are generally known for their various pharmacological effects including anti-inflammatory (Baricevic et al., 2001) , antioxidative (Wang et al., 1999) , antibacterial (Mašterová et al., 1996) and hepatoprotective effects (Amin and Hamza, 2005) . Various organic compounds of various biological activities were isolated from plants belonging to the genus Salvia L. like flavonoids (Lu and Foo, 2000) , phenolic acids (Wang et al., 1999) , royleanones (Mašterová et al., 1996) , apianane terpenoids (Miura et al., 2001) , pentacyclic triterpenes (Mašterová et al., 1989) . A number of triterpenoids were shown to act as promising antineoplastic agents (Setzer and Setzer, 2003) . Ursolic acid ( Fig. 1 ) effectively inhibits angiogenesis, invasion of tumour cells and metastasis; however the mechanism of activity is poorly understood (Ovesná et al., 2004) . One of the possibilities of cancer treatment is to suppress the activity of proteases (mainly urokinase, cathepsins, and metalloproteinases) that play an important role in tumour invasion and metastasis (Jediná k and Maliar, 2005) . Therefore, proteases present an attractive target in therapy and pharmaceutical research (Tossi et al., 2000; Maliar et al., 2004) . A very perspective strategy how to control proteases seems to be the development of selective low-molecular weight inhibitors from natural sources with possible lower toxicity. The selectivity of small-molecule inhibitors toward a protein or enzyme target is often of crucial importance in the development of therapeutically useful molecules (Mackman et al., 2001) . Thus inhibition of protease activity by selective low-molecular weight inhibitors represents a promising strategy for anticancer and antimetastatic therapy.
In this paper we studied the antiprotease activity of 16 natural products isolated from various plants on two neoplastic proteases, cathepsin B (cysteine protease) and urokinase (serine protease). We also studied the antiprotease activity of natural products to trypsin and thrombin considering the selective effect of tested compounds to urokinase, because the serine proteases have a common catalytic triad and except chymotrypsin also a similar binding site (Hedstrom, 2002) .
The strongest antiprotease activity to urokinase and cathepsin B was reported for ursolic acid with the inhibition activity IC 50 = 12 μm to urokinase and IC 50 = 10 μm to cathepsin B. Previously, an antiproliferative effect of ursolic acid against B16 melanoma cells (Es- Saady et al., 1996) has been reported. Therefore, we were looking whether ursolic acid is able to suppress the metastasis behaviour of cancer cells in vivo. We found, that ursolic acid suppresses the lung colonization of B16 melanoma cells in vivo.
Materials and Methods

Compounds
The alkaloids including berberine, berbamine, jatrorrhizine, magnoflorine, tetrahydroberberine, tetrahydrojatrorrhizine, tetrahydropalmatin were previously isolated from Mahonia aquifolium (Košt'á lová et al., 1981 (Košt'á lová et al., , 1986 Slavík et al., 1985) ; the (Mašterová et al., 1991) ; patuletin and patulitrin were isolated from Anthemis tinctoria L. (Mašterová et al., 1993) ; eupaline and eupatoline were isolated from Rudbeckia bicolor (Bukovský et al., 1994) , and the triterpenes -ursolic acid and -oleanolic acid were previously isolated from Salvia officinalis L. (Mašterová et al., 1989) . All tested compounds were isolated at the Department of Pharmacognosy and Botany, Faculty of Pharmacy, Comenius University in Bratislava, Slovakia and were identified by comparison of their 1 H,
13
C and mass spectra with published data. Purity of the tested compounds used in the present study was found to be higher than 96%.
Chemicals
Quercetin, tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) and dimethylsulfoxide (DMSO) were purchased from Fluka, Switzerland; Nα-benzoyl-d,l-arginine-4-nitroanilide hydrochloride (BApNA), trypsin from porcine pancreas (2000 BAEE units/mg), glycine-arginine paranitroanilide dihydrochloride (GapNA · 2HCl), urokinase from human kidney cells (10,000 Plough units/mg), Nα-benzoyl-phenylalanyl-valyl-arginineparanitroanilide (BPVA-pNA), thrombin (150 NIH units/mg), thiobenzyl benzyloxycarbonyl-llysinate (Cbz-Lys-SBzl), 5,5Ј-dithio-bis(2-nitrobenzoic acid) (DTNB), and cathepsin B (Cbz-Lysp-nitrophenyl ester units/mg) were purchased from Sigma, St. Louis, USA. For the in vitro enzyme assays a photometric microplate reader MRX II (Dynex, Chantilly, Virginia, USA) and Revelation 2.01 software (Dynex) were used.
Cells
B16, a mouse melanoma cell line derived from spontaneous skin tumour in C57B1/6 mouse, was obtained from the Cancer Research Institute, Slovak Academy of Science, Bratislava, Slovakia. The cells were grown in Eagles minimum essential medium (MEM) (BioWhittaker, Verviers, Belgium) supplemented with 10% heat-inactivated fetal calf serum (BioWhittaker), sodium pyruvate (KochLight Laboratories, Haverhill Suffolk, UK), l-glutamine (Sebak, Aidenbach, Germany) antibiotic. The cells were grown at 37 ∞C in a humidified atmosphere containing 5% CO 2 . B16 cells at a concentration of 0.5 ¥ l0 6 were plated and grown in a 25 cm 2 flask in 4 ml of complete culture medium.
Protease inhibition assay
Determination of natural products inhibition activity against trypsin, thrombin, urokinase and cathepsin B was done by simple photometry, using chromogenic substrates like BApNA for trypsin, GapNA · 2HCl for urokinase, BPVA-pNA for thrombin, and Cbz-Lys-SBzl in combination with DTNB for cathepsin B. The substrates were cleaved by trypsin, thrombin or urokinase according to the methods described earlier (Erlanger et al., 1961; Nieuwenhuizen et al., 1977) and for cathepsin B (Coleman and Green, 1981; Lottenberg et al., 1981) . Released chromogenic products are detectable photometrically at 410 nm. A convenient microplate screening system was used for the determination of protease inhibition activity of the compounds. The assay consisted of preparation of the microplate, start of the enzyme reaction and microplate measurements and data processing. The microplates were prepared manually using 8-channel pipettes (Dynex, Chantilly, Virginia, USA; Socorex, Ecublens/Lausanne, Switzerland) by gradual dissolution of the substrate-inhibitor mixture. Each well (two parallel wells were used) contained buffer solution with 0.6 mm concentration of substrate with 1% dimethylsulfoxide (DMSO) (v/v) and the chosen concentration of the tested compounds. Plates were started by enzyme solution 0.0015 mg/ml of trypsin Ð 3 BAEE units, 0.05 mg/ml of urokinase Ð 500 Plough units, thrombin 150 NIH units/mg in 0.05 m Tris-HCl buffer, pH 7.6, without Ca 2+ ions and 0.0106 mg/ ml of cathepsin B Ð 0.0555 units Cbz-Lys-paranitrophenyl ester in 0.1 m Sörensen phosphate buffer, pH 5.0. The temperature was set at 36.5 ∞C, data scanning time was 1 min and 61 min. Measurement data after conversion via text format were sent to a PC. IC 50 values were calculated for each compound, data processing was supported by statistic evaluation of the control wells (SD, %SD) and by the correlation factor. For each compound presented in this paper, several tests were performed. The average of IC 50 values was calculated from at least three parallel tests to fulfil the chosen percentage criterions of the standard deviation (%SD) Ð lower than 10% and the correlation factor of semilogarithmic plot % inhibition = f (log C) better than 0.95.
Animals
Male C57BL/6N mice (5 to 6 weeks old) were obtained from Velaz (Prague, Czech Republic). Mice were randomized into experimental groups (n = 6) receiving vehicle or daily i.p. treatments at the doses of 50, 75 and 100 mg/kg. All procedures were in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.
Lung colonization assay
Mice were injected with 5Ð7.5 ¥ 10 4 tumour cells in 0.1 ml PBS in the lateral tail vein. Treatments were administered i.p. daily, immediately after tumour cell injection during consecutive 16 d. Mice were killed by cervical dislocation 29 d after tumour cell injection. Lungs were fixed in Bouin's solution, and black tumour cell colonies counted.
Statistical analysis
All results are expressed as means ð standard deviation. Statistical evaluation of the data was done using Student's t-test.
Results and Discussion
The paper reports an in vitro antiprotease activity of 16 natural compounds previously isolated from five medicinal plants, Mahonia aquifolium, Calendula officinalis, Anthemis tinctoria, Rudbeckia bicolor, Salvia officinalis, which are used in traditional medicine in Slovakia. The antiprotease activities of natural compounds (7 alkaloids, 7 flavonoids and 2 triterpenes) are presented in Table  I . The compounds were tested on two neoplastic proteases, cathepsin B and urokinase. We also studied the antiprotease activity of natural products to trypsin and thrombin considering the selective effect of tested compounds to urokinase. From the results a considerable protease inhibition activity of selected compounds and a selective inhibition activity to one of tested proteases are evident. In fact, compounds were tested as perspective building blocks of potential anticancer agents taking into account the size of the molecules. The flavonoid quercetin was used as a standard for all tested proteases (Maliar et al., 2004; Mantle et al., 1999) .
The collection of the evaluated compounds includes several chemical groups: alkaloids (berberine, berbamine, jatrorrhizine, magnoflorine, tetrahydroberberine, tetrahydrojatrorrhizine, tetrahydropalmatin), flavonoids (isorhamnetin-
side, patuletin, patulitrin, eupaline, eupatoline), and triterpenes ( -ursolic acid and -oleanolic acid). The best candidates from the antiprotease efficiency point of view are the triterpenes isolated from Salvia officinalis with relatively high efficiency, related to the results of complete collection. The highest inhibition activity to urokinase as a rational drug target for the treatment of cancer and metastasis (Katz et al., 2000) was reported for -ursolic acid (IC 50 = 12 μm). The flavonoid quercetin used as a standard was little less effective (IC 50 = 14 μm) to urokinase than -ursolic acid. Moreover, -ursolic acid showed also high inhibition activity to cathepsin B (IC 50 = 10 μm), which represents another possible drug target for the suppression of tumor invasion and metastasis (Jediná k and Maliar, 2005) . Inhibition activity of -ursolic acid to cathepsin B was comparable to authentic quercetin (IC 50 = 11 μm). On the other hand, the highest inhibition activity to the protease trypsin, which is involved in pathogenesis of pancreatitis (Liddle and Nathan, 2004) , was reported for the flavonoid patuletin (IC 50 = 6.7 μm) isolated from Anthemis tinctoria. Patuletin showed more than two times higher activity than authentic quercetin (IC 50 = 15 μm). -Ursolic acid showed weaker inhibition activity (IC 50 = 10 μm) than patuletin, but a stronger activity than the standard quercetin. In addition, the natural compounds also showed inhibition activity to thrombin as one of the possible drug targets in the treatment of thromboembolic disorders (Katira et al., 2005) . -Ursolic acid exhibited comparable inhibition activity to thrombin (IC 50 = 30 μm) as the standard quercetin (IC 50 = 26 μm). The effect of -ursolic acid (Fig. 1) that inhibited in vitro cell growth of a large list of cancer cell lines including mouse melanoma B16 cells (EsSaady et al., 1996) was evaluated in vivo at daily i.p. doses of 50, 75, and 100 mg/kg. No mortality and no body weight changes were observed at chosen doses. The most perspective compound that potently inhibited proteases was tested for its abil- ity to inhibit lung colonization. The evaluation was made on the 29th day after tumour cell application. In all controls and treated groups of animals 6 animals/group were evaluated except for dose group 50 mg/kg (n = 5). In spite of a relative smaller number of lung colonies in the control group, the lungs of all animals with the lowest dose (50 mg/kg) were free of colonies. The macroscopic appearance of the lungs from untreated and treated mice clearly showed that ursolic acid at the dose of 50 mg/kg reduced the number of lung metastases after i.v. injection of B16 cells (Fig. 2) . We suggest that one of the possible explanations of lower effect at higher doses may be that the be associated with a wide range of effects of ursolic acid in tumorigenesis, tumor promotion and angiogenesis. However, the mechanism of ursolic acid activity is still poorly understood (Ovesná et al., 2004) and remains largely unknown (Setzer and Setzer, 2003; Hsu et al., 2004) . This reported antiprotease and antimetastatic effect of ursolic acid in vivo reflects the growing interest in research of triterpenoids as chemotherapy perspectives. The mechanism of ursolic acid action should be further investigated.
